HomeNews

News

  • New safety risks emerge for alemtuzumab in MS

    • April 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NICE denies Ocrelizumab for RRMS in UK

    • April 7, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Migraine associated with Increased Heart stroke risk, says recent analysis

    • April 6, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Roche Acquires regenerative MS therapy program focused on remyelination

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NATCO launches generic version of Aubagio for MS in INDIA

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • First patient enrolled in Ph 3 Trial of ADS-5102 in MS Patients with Walking Impairment

    • April 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Novel PET imaging agent to assess treatments for neurological diseases

    • April 4, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Dextromethorphan displays efficacy in Prophylactic Migraine treatment for patients with MS

    • April 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • NDA filing of Acute Migraine Treatment by Dr. Reddy’s Laboratories and Promius Pharma

    • April 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ocrevus shows higher efficacy than Rebif on NEDA in RRMS patients, a recent analysis shows

    • April 2, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more